Augmentation of Thrombin Generation in Neonates Undergoing Cardiopulmonary Bypass
We compared recombinant activated factor VII (rFVIIa) with three-factor prothrombin complex concentrate (3F-PCC) for the ability to augment thrombin generation (TG) in neonatal plasma after cardiopulmonary bypass (CPB).
Morbidity But Not Mortality Is Decreased After Off-Pump Coronary Artery Bypass Surgery
This retrospective study compared outcomes between on-pump and off-pump CABG from a large multicenter cohort of propensity-matched patients.
Identification of Modifiable Risk Factors for Acute Kidney Injury after Coronary Artery Bypass Graft Surgery in an Asian Population
We aimed to ascertain whether the lowest hematocrit during CPB, preoperative anemia, and intraoperative transfusion remained as independent modifiable risk factors associated with AKI in our prospective cohort of Asians.
Fibrinogen Recovery and Changes in Fibrin-Based Clot Firmness after Cryoprecipitate Administration in Patients Undergoing Aortic Surgery Involving Deep Hypothermic Circulatory Arrest
Cryoprecipitate may be used to treat bleeding in cardiac surgery. Its effects on plasma fibrinogen and fibrin clotting in this setting are poorly defined.
Augmentation of Thrombin Generation in Neonates Undergoing Cardiopulmonary Bypass
We compared recombinant activated factor VII (rFVIIa) with three-factor prothrombin complex concentrate (3F-PCC) for the ability to augment thrombin generation (TG) in neonatal plasma after cardiopulmonary bypass (CPB).
Safety and Effects of Two Red Blood Cell Transfusion Strategies in Pediatric Cardiac Surgery Patients: A Randomized Controlled Trial
For patients with a non-cyanotic congenital heart defect undergoing elective cardiac surgery, a restrictive RBC transfusion policy (threshold of Hb 8.0 g/dl) during the entire perioperative period is safe, leads to a shorter hospital stay and is less expensive.
Is Dilutional Coagulopathy Induced by Different Colloids Reversible by Replacement of Fibrinogen and Factor XIII Concentrates?
Coagulation and platelet function are impaired by all 3 colloids.
Red Blood Cell Transfusion: What is the Evidence When to Transfuse?
A restrictive transfusion strategy of administering red blood cell transfusion in patients with hemoglobin concentration of 7-8 g/dl in most patients is supported by randomized clinical trials.
Comparison of the Effects of Albumin 5%, Hydroxyethyl Starch 130/0.4 6%, and Ringer’s Lactate on Blood Loss and Coagulation after Cardiac Surgery
We randomly assigned 240 patients undergoing elective cardiac surgery to receive up to 50 ml kg-1 day-1 of either HA, HES, or Ringer's lactate (RL) as the main infusion fluid perioperatively.
Implementation of an Institutional Protocol for Rational Use of Blood Products and Its Impact on Postoperative of Coronary Artery Bypass Graft Surgery
We evaluated the short-term effects of implementation of a protocol for the rational use of blood products in the perioperative period of cardiac surgery.
Prospective Clinical Trial on dosage Optimizing of Tranexamic Acid in Non-Emergency Cardiac Surgery Procedures
After withdrawal of aprotinin in 2008 only tranexamic acid (TxA, Cyclocapron, Pfitzer, Germany) remains available as antihyperfibrinolytic agent in Europe.
Population Pharmacokinetics of Tranexamic Acid in Adults Undergoing Cardiac Surgery with Cardiopulmonary Bypass
The objectives of this study were to investigate the population pharmacokinetics (PK) of tranexamic acid (TA) given with either low- or high-dose continuous infusion schemes in adult cardiac surgery patients during cardiopulmonary bypass (CPB).